Ethris has reported preliminary results from a Phase 2a trial of ETH47, an experimental mRNA medicine administered through the nose. The study tested adults with mild-to-moderate asthma who were deliberately exposed to rhinovirus under controlled conditions.
The company’s announcement on 5 November describes an antiviral signal and numerical improvements in several clinical measures. The results are an early development step, not approval of a new treatment or proof that the product prevents asthma attacks in everyday use.
A small controlled trial
Fifty adults aged 18 to 65 received a single dose of ETH47 or placebo one day before exposure to rhinovirus A16. Participants continued stable maintenance asthma therapy and were followed through day 42. The study was randomised and placebo-controlled.
Ethris reported a 40-fold lower viral load on day two in the treatment group. Its lower-respiratory-symptom measure was the primary endpoint; the release describes numerical improvements rather than establishing a definitive clinical benefit across the wider patient population.
What still needs to be shown
The product is designed to make cells locally produce interferon lambda, part of the immune response. It is an investigational medicine, distinct from a conventional asthma inhaler or an authorised vaccine.
Larger studies will need to examine the size, reliability and duration of any benefit, as well as safety with further dosing. The announcement comes from the developer and reports topline findings. It is not a reason for patients to stop or replace prescribed asthma treatment.
